Clinical value of 99Tc m-HYNIC-PSMA SPECT/CT in biochemical recurrence of prostate cancer
10.3760/cma.j.cn321828-20230621-00182
- VernacularTitle:99Tc m－HYNIC－PSMA SPECT/CT在前列腺癌生化复发中的临床价值
- Author:
Zun ZHAO
1
;
Xinyu WU
;
Bo LI
;
Xin BAI
;
Jingqi SHI
;
Simiao LIU
;
Junling XU
;
Yongju GAO
Author Information
1. 郑州大学人民医院、河南省人民医院核医学科；河南省核医学新型分子探针与临床转化医学重点实验室，郑州 450003
- Keywords:
Prostatic neoplasms;
Neoplasm recurrence, local;
Prostate-specific membrane antigen;
Tomography, Emission-computed, single-photon;
Tomography, X-ray compu
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2024;44(4):230-234
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the value of 99Tc m-hydrazinonicotinamide (HYNIC)-prostate specific membrane antigen(PSMA) SPECT/CT imaging in biochemical recurrence of prostate cancer (PCa). Methods:From January 2018 to March 2023, 112 patients with biochemical recurrence of PCa (age (72.6±6.1) years) who underwent 99Tc m-HYNIC-PSMA SPECT/CT imaging in Henan Provincial People′s Hospital were retrospectively analyzed. According to the level of prostate specific antigen (PSA), patients were divided into 0.2 μg/L2 μg/L group. According to the Gleason score, patients were divided into Gleason score≥8 group and Gleason score <8 group. The detection rate between groups was analyzed by χ2 test, and the difference of the PSA level between groups was compared by Mann-Whitney U test. Results:PSMA imaging was positive in 77 cases and negative in 35 cases, with the detection rate of 68.8%(77/112). The detection rates of local recurrence, lymph node metastasis, bone metastasis and lung metastasis were 8.9%(10/112), 43.8%(49/112), 28.6%(32/112) and 0.9%(1/112), respectively. The detection rates of 0.2 μg/L2 μg/L groups were 44.7%(21/47), 8/12 and 90.6%(48/53), respectively ( χ2=24.44, P<0.001). The detection rates of Gleason score ≥8 group and <8 group were 76.4%(55/72) and 55.0%(22/40) ( χ2=5.47, P=0.032); the PSA level between the two groups was statistically different (3.11(0.75, 5.91) and 0.84(0.44, 2.92) μg/L; z=-2.99, P=0.003). Of the patients with PSMA positive imaging, 84.4%(65/77) changed their treatment regimen and 15.6%(12/77) continued to observe or maintain the original treatment plan. Of the patients with PSMA negative imaging, 40.0%(14/35) changed the treatment plan, 51.4%(18/35) continued to observe or maintain the original treatment plan, and 8.6%(3/35) discontinued the original treatment because no tumor metastasis was found. Conclusion:99Tc m-HYNIC-PSMA SPECT/CT imaging can provide reference for the lesion detection, treatment decision-making and follow-up observation of biochemical recurrence of PCa.
